| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |